Online Only Articles

A phase 1 trial of alisertib and romidepsin for relapsed/refractory aggressive B-cell and T-cell lymphomas

Division of Cancer Medicine, MD Anderson Cancer Center, Houston, TX
Department of Lymphoma and Myeloma, MD Anderson Cancer Center, Houston, TX
Department of Lymphoma and Myeloma, MD Anderson Cancer Center, Houston, TX
Department of Lymphoma and Myeloma, MD Anderson Cancer Center, Houston, TX
Department of Lymphoma and Myeloma, MD Anderson Cancer Center, Houston, TX
Department of Lymphoma and Myeloma, MD Anderson Cancer Center, Houston, TX
Department of Lymphoma and Myeloma, MD Anderson Cancer Center, Houston, TX
Department of Lymphoma and Myeloma, MD Anderson Cancer Center, Houston, TX
Department of Lymphoma and Myeloma, MD Anderson Cancer Center, Houston, TX
Department of Lymphoma and Myeloma, MD Anderson Cancer Center, Houston, TX
Department of Lymphoma and Myeloma, MD Anderson Cancer Center, Houston, TX
Department of Lymphoma and Myeloma, MD Anderson Cancer Center, Houston, TX
Investigational Drug Branch of CTEP, National Cancer Institute, Bethesda, MD, USA
Department of Lymphoma and Myeloma, MD Anderson Cancer Center, Houston, TX
Department of Lymphoma and Myeloma, MD Anderson Cancer Center, Houston, TX
Vol. 105 No. 1 (2020): January, 2020 https://doi.org/10.3324/haematol.2019.220012